YAP1 and neoplasm: For example, palmitoylation inhibitors (by Vivace Therapeutics and Dana Farber) were shown to suppress tumor growth in strictly YAP/TAZ-dependent NF2-deficient tumors, such as mesothelioma, schwannoma, and meningioma [199,200,201].